US Food and Drug Administration (USFDA) has completed inspection at Aurobindo Pharma’s Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad. The inspection was carried out between November 4, 2019 to November 13, 2019. At the end of the inspection, the company has been issued a Form 483 with 14 observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
